Eleftha 150 mg Injection is an anti-cancer medicine used in the treatment of HER2-positive Breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is a disease where the cells grow abnormally and divide uncontrollably. It can also be used when the cancer has spread to other parts of the body.

Eleftha 150 mg Injection contains Trastuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the abnormal growth of cancer cells and, finally, causes the initiation of programmed cell death.

Eleftha 150 mg Injection may cause certain side effects such as abdominal pain, chills, diarrhoea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and injection site reactions. If the side effects persist or bother you, please consult your doctor. Eleftha 150 mg Injection will be administered by a trained doctor. Hence, do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Eleftha 150 mg Injection or its components. Inform your doctor if you have any cardiovascular conditions, lung problems, or liver/kidney disease, as it can cause adverse effects. Eleftha 150 mg Injection is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Eleftha 150 mg Injection is used in the treatment of Breast Cancer and Stomach Cancer. The detailed uses of Eleftha 150 mg Injection are as follows:

• HER2-Positive Breast Cancer: Eleftha 150 mg Injection is used in the treatment of breast cancer and used alone or with other agents to slow disease progression.
• HER2-Positive Gastric and Gastroesophageal Junction Cancer: Eleftha 150 mg Injection is used in treatment of HER2-Positive Gastric and Gastroesophageal Junction Cancer or in combination with chemotherapy for advanced or metastatic cases.

• Follow your doctor’s instructions on the dosage and timing of this medication.
• Eleftha 150 mg Injection will be administered in a hospital setting under the supervision of a physician qualified by training and experience to administer cancer chemotherapeutic agents.
• Do not self-administer.

Eleftha 150 mg Injection contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

Eleftha 150 mg Injection should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any lung problems, cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Eleftha 150 mg Injection may cause left ventricular ejection fraction, cardiomyopathy, pulmonary toxicity, exacerbations of chemotherapy-induced neutropenia, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. Eleftha 150 mg Injection may cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Eleftha 150 mg Injection is not recommended for use in children as the safety and efficacy are not established.